Acceleron Pharma (XLRN) Misses Q4 EPS by 32c

Acceleron Pharma (NASDAQ: XLRN) reported Q4 EPS of ($0.55), $0.32 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $3.8 million versus the consensus estimate of $9.6 million.

For earnings history and earnings-related data on Acceleron Pharma (XLRN) click here.

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• Axis Capital Limited Downgrades National Aluminium (NACL:IN) to Sell (4)
• UBS Downgrades Borouge PLC (BOROUGE:UH) to Neutral